Welcome to BioSeeker Group!

Triple Analysis: Angiogenesis, Antibodies and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5078
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Angiogenesis, Antibodies and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Angiogenesis and by the two compound strategies of Antibodies and Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Antibodies and Peptides.

    To find out more about Triple Analysis: Angiogenesis, Antibodies and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Antibodies and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Angiogenesis and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part II: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Affymax
Agennix
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Aileron Therapeutics
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Allostera
Allosterix
Alnylam
ALSP
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Amphora
Anchor Therapeutics
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ardana
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Baxter International
Bayer
Berkeley Lab
BioAlliance Pharma
BioAxone
Biocad
Biocon
Biogen Idec
BioInvent
Biokine Therapeutics
Biolex
BioLineRx
Biosceptre
Biotecnol
Biotest
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
Chiasma
China Sky One Medical
Choongwae
Circadian Technologies
Cleveland BioLabs
Clinuvel
Compugen
CSL
Cue Biotech
CuraGen
Curaxis
CureTech
Curis
Customized Therapeutics
Cyclacel
CytImmune Sciences
Cytochroma
Daiichi Sankyo
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Digna Biotech
Dompe
Dongkook Pharm
Dr Reddy’s
Dyax
Eisai
Elan
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Ergon Pharmaceuticals
Esperance Pharmaceuticals
EUSA Pharma
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Formula Pharmaceuticals
Fusion Antibodies
Galaxy Biotech
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
Genomic Systems
GENova Biotherapeutics
Genovax
GenPat77
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Glycotope
GP Pharm
Green Cross
Gryphon Therapeutics
Hawthorn Pharmaceuticals
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Immutep
Innate Pharma
InNexus Biotechnology
Innovive
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
Kaketsuken
KaloBios
Karus Therapeutics
Karyon-CTT
Kirax
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Kyto Biopharma
Lee’s Pharmaceutical
LFB Biotechnologies
LG Life Sciences
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Meda
Medarex
MediGene
MedImmune
Mediolanum
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Morvus Technology
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Neuren
Neurobiological Technologies
NewSouth Innovations
Nidus Laboratories
NIH
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
Novelix
Noxxon
NPS Pharmaceuticals
Oasmia
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Onyvax
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanGenetics
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacopeia
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
Protagonist
Protein Sciences
Protgen
PTC Therapeutics
Q Chip
QLT
Ramot
Raptor Pharmaceutical
Recepta biopharma
Receptor BioLogix
Regeneron
Rexahn
Rigel
Sanofi
Santaris Pharma
Sarepta Therapeutics
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Serometrix
Shanghai CP Guojian
Shenogen
Shionogi
Shire
Simcere Pharmaceuticals
Soligenix
Spear Therapeutics
Spectrum Pharmaceuticals
SRI International
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
SynerGene Therapeutics
Tactic Pharma
Taiho
Takeda
Tamir Biotechnology
Targa Therapeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
Unigene
United Biomedical
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Wilex
Viragen
Viventia Biotech
XBiotech
Xencor
Xerion
Xigen
Xoma
Y’s Therapeutics
YM BioSciences
Zelos Therapeutics
Zenotech
Zensun
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
abarelix
ABT-510
adecatumumab
AEZS-108
afamelanotide
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
angiopep+paclitaxel
Angiozyme
apatinib
ARQ-197
atrasentan
AV-299
axitinib
belimumab
bevacizumab
BHQ880
BIBF-1120
blinatumomab
BMS-663513
BMS-690514
BMS-936558
brentuximab vedotin
brivanib alaninate
BT-062
carlumab
catumaxomab
CBP-501
CDX-1307
CDX-1401
cediranib
cetuximab
cilengitide
cixutumumab
CMAB302
CMAB304
conatumumab
corticorelin acetate
CT-011
dalotuzumab
daratumumab
denosumab
deslorelin
DI-17E6
dovitinib lactate
E-75
E-7820
elotuzumab
EMD-273063
EMD525797
emepepimut-S
endostatin
ENMD-2076
enzastaurin hydrochloride
EP-100
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
foretinib
fosbretabulin tromethamine
FPI-01
fresolimumab
galiximab
ganitumab
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GliaAtak
goserelin
GS-6634
GT-111
GV-1001
GX-301
HBP-347
Her-2/Neu peptides
histrelin
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
imMucin
inotuzumab ozogamicin
intetumumab
IPH-2102
ipilimumab
IPP-204106
iratumumab
ISA-P53-01
JI-101
kahalalide F
L19-TNFalpha
lanreotide
lenvatinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
linifanib
lintuzumab
LIP-131I
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY-2275796
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDX-1379
MEDI-551
MEDI-573
MGCD-265
midostaurin
milatuzumab
milatuzumab-doxorubicin
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
motesanib diphosphate
moxetumomab pasudotox
muparfostat (IV)
NAFB001
naptumomab estafenatox
natalizumab
necitumumab
netupitant
NGR-TNF
nimotuzumab
obinutuzumab
octreotide
octreotide, LAR
ofatumumab
olaratumab
ON-01910
onartuzumab
Onyvax-105
oregovomab
OTS-102
ozarelix
paclitaxel
PancAtak
panitumumab
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PCI-27483
pegdinetanib
pertuzumab
PF-4856884
plitidepsin
polyclonal antibody stimulator
ponatinib
ProstAtak
PTC-299
RAF-265
ramucirumab
Reditux
regorafenib
RG-7160
ridaforolimus
rilotumumab
rindopepimut
rituximab
robatumumab
romiplostim
romurtide
samalizumab
SAR-3419
siltuximab
sirolimus
sorafenib tosylate
sotatercept
SU-6668
sunitinib malate
Survivac
Sym-004
talactoferrin alfa
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
thymalfasin
tigatuzumab
tipifarnib
tivozanib
TM-30339
tocilizumab
TRC-105
tremelimumab
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
vandetanib
vapreotide, immediate-release
veltuzumab
vismodegib
vitespen
volociximab
VX-001
XL-184
XL-647
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Antibodies and Peptides.
    To find out more about Triple Analysis: Angiogenesis, Antibodies and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Antibodies and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Leukemia and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the mechanism/target/effect of Apoptosis. Learn More


Cancer Vaccines: Aim and Shoot
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. Learn More